ViewRay, Inc. (VRAY) Analysts See $-0.15 EPS

February 15, 2018 - By Migdalia James

 ViewRay, Inc. (VRAY) Analysts See $ 0.15 EPS

Analysts expect ViewRay, Inc. (NASDAQ:VRAY) to report $-0.15 EPS on March, 15.They anticipate $0.10 EPS change or 40.00 % from last quarter’s $-0.25 EPS. After having $-0.19 EPS previously, ViewRay, Inc.’s analysts see -21.05 % EPS growth. The stock increased 2.45% or $0.2 during the last trading session, reaching $8.37. About 400,262 shares traded. ViewRay, Inc. (NASDAQ:VRAY) has risen 34.94% since February 15, 2017 and is uptrending. It has outperformed by 18.24% the S&P500.

ViewRay, Inc., through its subsidiary, ViewRay Technologies, Inc., designs, makes, and markets radiation therapy systems. The company has market cap of $566.26 million. It offers MRIdian, a radiation therapy solution that enables treatment and real-time imaging of a patient's anatomy simultaneously. It currently has negative earnings. MRIdian integrates MRI technology, radiation delivery, and proprietary software to locate, target, and track the position and shape of soft-tissue tumors while radiation is delivered.

Another recent and important ViewRay, Inc. (NASDAQ:VRAY) news was published by which published an article titled: “Fosun International Ltd Buys ViewRay Inc, Colony NorthStar Inc, iKang …” on February 09, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.